| Literature DB >> 30042685 |
Yonghao Feng1, Aiqun Chu2, Qiong Luo3, Men Wu1, Xiaohong Shi1, Yinghui Chen3.
Abstract
Currently, there are no effective treatments for diabetes-related cognitive dysfunction. Astaxanthin (AST), the most powerful antioxidant in nature, exhibits diverse biological functions. In this study, we tried to explore whether AST would ameliorate cognitive dysfunction in chronic type 2 diabetes mellitus (T2DM) rats. The T2DM rat model was induced via intraperitoneal injection of streptozotocin. Forty Wistar rats were divided into a normal control group, an acute T2DM group, a chronic T2DM group, and an AST group (treated with AST at a dose of 25 mg/kg three times a week). The Morris water maze test showed that the percentage of time spent in the target quadrant of the AST group was identical to that of the chronic T2DM group, while the escape latency of the AST group was decreased in comparison to that of the chronic T2DM group. Histology of the hippocampus revealed that AST ameliorated the impairment in the neurons of diabetic rats. Western blot showed that AST could upregulate nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) expression and inhibit nuclear transcription factor kappa B (NF-κB) p65 activation in the hippocampus. We found that AST increased the level of superoxide dismutase (SOD) and decreased the level of malondialdehyde (MDA) in the hippocampus. In addition, the levels of interleukin 1 beta (IL-1β) and interleukin 6 (IL-6) were reduced in the AST group compared with those in the chronic T2DM group. The findings of this research imply that AST might inhibit oxidative stress and inflammatory responses by activating the Nrf2-ARE signaling pathway.Entities:
Keywords: Nrf2; astaxanthin; cytokines; inflammatory response; oxidative stress; type 2 diabetes mellitus
Year: 2018 PMID: 30042685 PMCID: PMC6048598 DOI: 10.3389/fphar.2018.00748
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Effect of AST on the blood glucose level in each group (unit: mmol/l).
| Time | Control | aT2DM | cT2DM | AST |
|---|---|---|---|---|
| 6th week | 2.45 ± 0.59 | 2.97 ± 0.63 | 19.21 ± 1.20∗∗ | 19.09 ± 1.28∗∗ |
| 12th week | 2.82 ± 0.35 | 18.58 ± 1.32 | 18.27 ± 1.13 | 18.09 ± 1.29 |